CRISPR Q2 Revenue Rose 151% YoY As FDA Approved CASGEVY for Children Aged 2+

CRISPR Therapeutics reported strong second-quarter financial results with CASGEVY revenue rising 151% year-over-year. The FDA recently expanded CASGEVY approval to children as young as 2 years old, while the company initiated new Phase 1 trials for in vivo candidates CTX340 and CTX460.